Colley v. Orexigen Therapeutics, Inc. et al
Filing
155
ORDER: (1) Granting Unopposed Motion for Final Approval of Settlement and Plan of Allocation; (2) Granting Motion for an Award of Attorneys' Fees and Expenses; and (3) Entering Judgment [ECF Nos. 149; 150]. Signed by Judge Janis L. Sammartino on 11/30/2021. (tcf)
1
2
3
4
5
6
7
8
UNITED STATES DISTRICT COURT
9
SOUTHERN DISTRICT OF CALIFORNIA
10
11
12
KARIM KHOJA, et al., on behalf of
himself and all others similarly situated,
15
16
ORDER:
Plaintiffs,
13
14
Case No.: 15-cv-00540-JLS-AGS
v.
(1) GRANTING UNOPPOSED
MOTION FOR FINAL APPROVAL
OF SETTLEMENT AND PLAN OF
ALLOCATION;
OREXIGEN THERAPEUTICS, INC., et
al.,
Defendants.
17
(2) GRANTING MOTION FOR AN
AWARD OF ATTORNEYS’ FEES
AND EXPENSES; AND
18
19
(3) ENTERING JUDGMENT
20
21
[ECF Nos. 149; 150]
22
23
Presently before the Court are Lead Plaintiff Karim Khoja’s Unopposed Motions
24
for: (1) Final Approval of Settlement and Plan of Allocation (“Final Approval Motion”)
25
(ECF No. 149); and (2) an Award of Attorneys’ Fees and Litigation Expenses (“Fees
26
Motion”) (ECF No. 150). The Court held a Final Approval Hearing regarding both motions
27
on October 28, 2021. (ECF No. 154.) As set forth during the Hearing, because the
28
Settlement and Plan of Allocation are fair, reasonable, and adequate, the Court GRANTS
1
15-cv-00540-JLS-AGS
1
the Final Approval Motion. Further, because the requested attorneys’ fees, litigation
2
expenses, and incentive award, are reasonable the Court GRANTS the unopposed Fees
3
Motion.
4
BACKGROUND
5
This case began over six years ago on March 10, 2015, when the first of three initial
6
complaints in this action was filed alleging that Defendant Orexigen Therapeutics, Inc.
7
(“Orexigen”) “made materially misleading statements when it disclosed confidential
8
25[ percent] interim data from a large-scale clinical trial . . . of its weight loss drug,
9
Contrave,” on March 3, 2015. (ECF No. 149-2 (“Abadou Decl.”) ¶ 2.) The news that
10
Contrave may demonstrate cardioprotective benefits caused Orexigen’s stock to close
11
“31[ percent] higher than it did the day prior.” (Id.) A March 5, 2015 Forbes.com article,
12
however, reported that “a senior FDA official condemned [Orexigen]’s disclosure, . . .
13
causing the stock price to plummet and erasing more than $280 million in market
14
capitalization.” (Id.)
15
Several related cases were filed premised on the same facts (id. ¶ 11), and on June
16
22, 2015, the Honorable M. James Lorenz ordered the cases consolidated, appointed Karim
17
Khoja (“Lead Plaintiff” or “Plaintiff”) as lead plaintiff, and approved Kahn Swick & Foti,
18
LLP (“Lead Counsel”) as lead counsel (ECF No. 43). (Abadou Decl. ¶ 12.) On June 26,
19
2015, Judge Lorenz recused himself from the case, and this Court was reassigned. (ECF
20
No. 46.)
21
On August 20, 2015, Plaintiff filed a Consolidated Complaint (ECF No. 55), which
22
added allegations of further misleading statements made by Orexigen on March 3 and May
23
8, 2015. (Abadou Decl. ¶¶ 12–13.) Defendants Orexigen, Joseph P. Hagan, Michael A.
24
Narachi, and Preston Klassen (collectively, “Defendants”) filed a Motion to Dismiss the
25
Consolidated Complaint (ECF No. 62), which the Court granted with leave to amend (ECF
26
No. 76). (Abadou Decl. ¶ 14.) Thereafter, Plaintiff requested that the Court enter judgment
27
in Defendants’ favor so he could pursue an appeal (ECF No. 77) and subsequently appealed
28
the Court’s dismissal decision (ECF No. 80). (Abadou Decl. ¶ 14.) On March 12, 2018,
2
15-cv-00540-JLS-AGS
1
while the appeal was pending, Orexigen filed for Chapter 11 bankruptcy, and an automatic
2
stay halted further proceedings against Orexigen, but not the remaining defendants
3
(collectively, the “Individual Defendants”). (Id. ¶¶ 16, 36; see also id. ¶¶ 46–52.)
4
On August 13, 2018, the Ninth Circuit affirmed in part and reversed in part the
5
Court’s dismissal of the Consolidated Complaint (ECF No. 93). (Abadou Decl. ¶¶ 15, 37.)
6
The Individual Defendants filed petitions for panel rehearing and rehearing en banc (ECF
7
No. 85), but the Ninth Circuit denied the petitions (ECF No. 86). (Abadou Decl. ¶¶ 38–
8
41.) The Individual Defendants then filed a petition for writ of certiorari with the Supreme
9
Court, but the Court denied certiorari (ECF No. 108). (Abadou Decl. ¶¶ 43–45.)
10
Following an Appeal Mandate Hearing on January 7, 2019, (ECF No. 92), this Court
11
issued a briefing schedule for the Individual Defendants to file a renewed motion to dismiss
12
(ECF No. 97). (Abadou Decl. ¶ 53.) On September 23, 2019, the Court granted in part
13
and denied in part the Individual Defendants’ Renewed Motion to Dismiss (ECF Nos. 98;
14
110). (Abadou Decl. ¶ 55.) On October 17, 2019, Plaintiff filed a Consolidated Amended
15
Complaint (“CAC”) (ECF No. 111), which the Individual Defendants moved to dismiss
16
(ECF No. 114). (Abadou Decl. ¶¶ 56–57.)
17
On March 13, 2020, the parties participated in a day-long mediation facilitated by
18
Jed Melnick, Esq., of JAMS. (Id. ¶¶ 63–64.) After reaching an impasse, the parties
19
adjourned but agreed that they would resume settlement discussions after the Court ruled
20
on the Individual Defendants’ pending Partial Motion to Dismiss. (Id. ¶ 64.)
21
On May 19, 2020, after Orexigen’s Wind Down Administrator, Province, Inc.
22
(“Province”), filed a status report with the Ninth Circuit reporting that the bankruptcy stay
23
had been lifted, the Ninth Circuit extended its prior order to Orexigen, and the mandate,
24
which noted the substitution of Province for Orexigen, was spread to this Court on July 10,
25
2020 (ECF No. 134). (See Abadou Decl. ¶ 59.)
26
On November 2, 2020, the Court granted the Individual Defendants’ Partial Motion
27
to Dismiss (ECF No. 139). (Abadou Decl. ¶ 62.) Thereafter, the parties resumed
28
settlement negotiations, and, after several weeks of additional negotiations, agreed to
3
15-cv-00540-JLS-AGS
1
accept a mediator’s proposal of $4.8 million. (Id. ¶¶ 64–65.) On December 9, 2020, the
2
parties completed and executed a Settlement Term Sheet and filed a Notice of Settlement
3
(ECF No. 140) requesting that the Court set a date for Plaintiff to move for preliminary
4
approval of the parties’ settlement. (Abadou Decl. ¶ 66.) The Court subsequently ordered
5
Plaintiff to file a motion for preliminary approval of the settlement by February 12, 2021
6
(ECF No. 141). (Abadou Decl. ¶ 66.) Plaintiff filed an Unopposed Motion for Preliminary
7
Approval of Proposed Settlement on February 12, 2021, (ECF No. 142), and the Court
8
granted preliminary approval on April 22, 2021 (ECF No. 147). (Abadou Decl. ¶ 68.) On
9
May 18, 2021, the $4.8 million Settlement Amount was paid into an interest-bearing
10
escrow account on behalf of the Settlement Class. (Id. ¶ 69.) Plaintiff’s Final Approval
11
and Fees Motions now follow.
12
SETTLEMENT TERMS
The Proposed Settlement1 preliminarily approved by this Court defines the
13
14
Settlement Class as:
15
“all Persons who purchased or otherwise acquired Orexigen
publicly traded securities between March 3, 2015 and May 12,
2015, inclusive,” excluding “Defendants, all directors and
officers of Orexigen (whether current or former), each of their
respective immediate family members, and entities in which any
such excluded person holds a controlling interest.”
16
17
18
19
20
(ECF No. 147 (“Prelim. App. Order”) at 4 (quoting ECF No. 142-3 ¶ 1.26).)2 The
21
Settlement provides for a $4.8 million Settlement Amount less the following deductions:
22
the reasonable costs and expenses of the Claims Administrator incurred in connection with
23
24
25
26
27
28
Capitalized terms used herein have the same meaning as set forth in the Court’s
Preliminary Approval Order (ECF No. 147) and the Stipulation of Settlement (ECF No.
142-3) unless otherwise defined.
2
Citations to page numbers of documents on the docket are to the page numbers
assigned by the CM/ECF system.
1
4
15-cv-00540-JLS-AGS
1
providing notice and administrating the settlement (not to exceed $250,000); certain taxes
2
and tax expenses; Lead Counsel’s fees (not to exceed 33 percent of the Settlement
3
Amount); and Lead Counsel’s and Lead Plaintiff’s expenses (not to exceed $185,000). (Id.
4
(citing ECF Nos. 142-3 ¶ 6.2; 142-5 at 1).) The remaining balance, i.e., the Net Settlement
5
Fund, is to be distributed to Authorized Claimants. (Id.)
6
Each Settlement Class Member who wishes to receive a portion of the Net
7
Settlement Fund must submit a Proof of Claim and Release Form by the date provided in
8
the Proposed Notice, and any Settlement Class Member who fails to submit a timely Proof
9
of Claim and Release Form will be barred from receiving payment but otherwise bound by
10
the terms of the Settlement. (Id. (citing ECF No. 142-3 ¶ 6.3(b)).) Before the deduction
11
of fees, costs, and expenses, Plaintiff’s damages expert estimates the average recovery per
12
share to be $0.19, if valid claims are submitted for all approximately 25 million shares of
13
Orexigen securities purchased during the Class Period. (Id. at 5 (citing ECF No. 142-5
14
¶ 3).)
15
Each Authorized Claimant will receive a pro rata share of the Net Settlement Fund
16
based on a recognized loss formula, which varies for common stock, call options, and put
17
options. (Id. (citing ECF No. 142-5 ¶¶ 49–71).) In exchange, the Class Members:
18
19
20
21
22
23
24
25
26
27
28
shall have fully, finally, and forever waived, released,
relinquished, discharged, and dismissed with prejudice all
Released Claims against all Released Defendant Parties, and
shall forever be barred and enjoined from commencing,
instituting, intervening in or participating in, prosecuting or
continuing to prosecute any action or other proceeding in any
court of law or equity, arbitration tribunal, or administrative
forum, or other forum of any kind of character (whether brought
directly, in a representative capacity, derivatively, or in any other
capacity), that asserts any of the Released Claims against any of
the Released Defendant Parties, regardless of whether such
Settlement Class Member executed and delivers a Proof of Claim
and Release Form, and whether or not such Settlement Class
Member shares in the Settlement Fund.
(Id. (quoting ECF No. 142-3 ¶ 5.1).)
5
15-cv-00540-JLS-AGS
1
2
MOTION FOR FINAL APPROVAL
I.
Class Certification
3
A threshold requirement for final approval of a class action settlement is the
4
assessment of whether the class satisfies the requirements of Federal Rule of Civil
5
Procedure 23(a) and the requirements of one of the types of class actions enumerated in
6
subsection (b). Hanlon v. Chrysler Corp., 150 F.3d 1011, 1022 (9th Cir. 1998), overruled
7
on other grounds by Wal-Mart Stores, Inc. v. Dukes, 564 U.S. 338 (2011). Here, in the
8
Preliminary Approval Order, the Court found the proposed Settlement Class proper and
9
certified it for settlement purposes. (Prelim. App. Order at 5–11.) Because “[t]here have
10
been no changes with respect to factors this Court considered in preliminarily certifying
11
the Settlement Class” (Final App. Mot. at 30), the Court incorporates by reference the
12
reasons set forth in its Preliminary Approval Order and reaffirms that the requirements of
13
Rule 23(a) and (b) have been satisfied.
14
II.
Adequacy of Notice
15
Before granting final approval, a court must also determine whether the class
16
received adequate notice of the settlement. Hanlon, 150 F.3d at 1025. Here, in the
17
Preliminary Approval Order, the Court approved the content of the forty-eight-page
18
Proposed Notice, the Proof of Claim and Release Form, and the proposed notification plan
19
and authorized Rust Consulting, Inc. (“Rust”) to act as the Claims Administrator in
20
connection with the Settlement. (Prelim. App. Order at 15–17.) In support of the Final
21
Approval Motion, Plaintiff attached the Declaration of Jason Rabe, a program manager for
22
Rust. (ECF No. 149-7 (“Rust Decl.”) ¶ 1.) Pursuant to the Preliminary Approval Order
23
and Proposed Settlement, Rust mailed a Notice Packet (consisting of the Notice and Proof
24
of Claim and Release Form) on or around May 12, 2021, to 4,016 mailing records of
25
common banks, brokers, and other nominees. (Rust Decl. ¶ 2; Abadou Decl. ¶ 71.) The
26
Notice requested that, within ten days of receipt, these brokers and nominees identify
27
potential Class Members by their names and addresses, forward a copy of the Notice Packet
28
to these potential Class Members, and provided Lead Counsel with written confirmation
6
15-cv-00540-JLS-AGS
1
of doing so. (Rust Decl. ¶ 4.) As of September 23, 2021, the date of the Rust Declaration’s
2
execution:
3
4
5
6
7
8
9
• Rust had received an additional 6,902 names and addresses of potential Class
Members from individuals at brokerage firms, banks, institutions, and other
nominees.
• Rust received requests from brokers and other nominee holders for 4,920 additional
Notice Packets.
• 1,520 Notice Packets were returned to Rust by the United States Postal Service as
undeliverable, but 182 new addresses were obtained.
• A total of 16,074 Notice Packets were mailed to potential Class Members.
(Id. ¶¶ 5–8.)
10
Rust also engaged in a number of additional efforts to notify potential Class
11
Members of the Settlement. On May 12, 2021, Rust established a case-specific, toll-free
12
number with an Interactive Voice Response System and live operators to respond to
13
inquiries about the Settlement. (Id. ¶ 10.) From May 12, 2021, to September 23, 2021,
14
Rust received forty-seven calls to the telephone hotline. (Id. ¶ 11.) Also on May 12, 2021,
15
Rust established a case-specific website with general information about the instant matter
16
and downloadable copies of the Notice, Proof of Claim and Release Form, Summary
17
Notice, and other settlement documents. (Id. ¶ 12.) Additionally, on May 24, 2021, in
18
accordance with the Preliminary Approval Order, Rust released the Summary Notice to be
19
published in the national edition of Investor’s Business Daily. (Id. ¶ 9.) As of October 19,
20
2021, Rust had received 3,123 Proof of Claims and Release Forms. (ECF No. 153-2
21
(“Supp. Rust Decl.” ¶ 2.)
22
Having reviewed the Rust Declaration, which provides that notice was disseminated
23
to potential Class Members in the manner ordered by the Court in its Preliminary Approval
24
Order, and the Supplemental Rust Declaration attached to Plaintiff’s reply, the Court finds
25
that the Settlement Class received adequate notice of the Settlement.
26
III.
Fairness of the Settlement
27
Before granting final approval, a court must also examine whether the settlement is
28
fair, adequate, and reasonable. Fed. R. Civ. P. 23(e). The Ninth Circuit has enumerated
7
15-cv-00540-JLS-AGS
1
various factors that district courts should consider and balance in determining whether a
2
proposed settlement meets the fair, reasonable, and adequate standard, including: (1) the
3
strength of the plaintiff’s case; (2) the risk, expense, complexity, and likely duration of
4
further litigation; (3) the risk of maintaining class action status throughout trial; (4) the
5
amount offered in settlement; (5) the extent of discovery completed and the stage of the
6
proceedings; (6) the experience and views of counsel; (7) the presence of a governmental
7
participant; and (8) the reaction of the class members to the proposed settlement. Hanlon,
8
150 F.3d at 1026. This fairness determination is committed to the sound discretion of the
9
district court. Id. Additionally, “[w]here a settlement is the product of arms-length
10
negotiations conducted by capable and experienced counsel, the court begins its analysis
11
with a presumption that the settlement is fair and reasonable.” Garner v. State Farm Mut.
12
Auto Ins. Co., No. CV 08 1365 CW (EMC), 2010 WL 1687832, at *13 (N.D. Cal. Apr. 22,
13
2010).
14
A.
15
Negotiation at Arm’s Length with the Assistance of an Experienced, Neutral
Mediator
16
As detailed by Plaintiff in his Final Approval Motion, the Settlement here was
17
reached with the assistance of an experienced, neutral mediator after “six years of hard-
18
fought litigation, extensive mediation[,] and several months of settlement negotiations.”
19
(Final App. Mot. at 15–16.) Indeed, the Court has already found, and again finds, that the
20
Settlement “was the product of serious, informed, and non-collusive negotiations” (ECF
21
No. 147 at 12) with experienced and well-respected counsel on both sides. See In re
22
Immune Response Sec. Litig., 497 F. Supp. 2d 1166, 1174 (S.D. Cal. 2007) (“Both [p]arties
23
are represented by experienced counsel and their mutual desire to adopt the terms of the
24
proposed settlement, while not conclusive, is entitled to a great deal of weight.” (citing
25
Williams v. Vukovich, 720 F.2d 909, 922–23 (6th Cir. 1983); Cotton v. Hinton, 559 F.2d
26
1326, 1330 (5th Cir. 1977))). Accordingly, the Court begins its fairness examination with
27
a presumption that the Settlement is fair and reasonable. See Garner, 2010 WL 1687832,
28
at *13.
8
15-cv-00540-JLS-AGS
1
B.
2
Strength of Plaintiff’s Case and the Risk, Expense, Complexity, and Likely
Duration of Further Litigation
3
The potential strengths and weakness of Plaintiff’s case, and the risk, expense,
4
complexity, and likely duration of further litigation all support final approval of the
5
Settlement. In the Final Approval Motion, Plaintiff acknowledges that this action, brought
6
pursuant to the Private Securities Litigation Reform Act (“PSLRA”), “was inherently risky
7
and difficult from the outset.” (Final App. Mot. at 18 (citing Scott v. ZST Digit. Nets., Inc.,
8
Case No. CV 11-3531 GAF (JCx), 2013 WL 12126744, at *3 (C.D. Cal. Aug. 5, 2013)
9
(“[C]ases brought under [PSLRA] . . . involve a ‘heightened level of risk’ because PSLRA
10
‘makes it more difficult for investors to successfully prosecute securities class actions.’”)).)
11
And to recover under § 10(b) of the Securities Exchange Act and Rule 10(b)-5, Plaintiff
12
would have had to prove: (1) a material misrepresentation or omission; (2) scienter; (3) a
13
connection between the misrepresentation or omission and the purchase or sale of a
14
security; (4) reliance upon the misrepresentation or omission; (5) economic loss; and
15
(6) loss calculation. Halliburton Co. v. Erica P. John Fund, Inc., 573 U.S. 258, 267 (2014)
16
(quoting Amgen Inc. v. Ct. Ret. Plans & Tr. Funds, 568 U.S. 455, 460–61 (2013)).
17
Throughout this case, Defendants have “vigorously den[ied] liability,” and notably,
18
challenged the scienter element—“one of the more difficult elements of a securities fraud
19
claim”—in their Motion to Dismiss the Consolidated Complaint (ECF No. 98), arguing
20
that they acted in good faith and did not have motive to commit fraud. (Abadou Decl.
21
¶¶ 77, 81 (citing In re Amgen Inc. Sec. Litig., Case No. CV 7-2536 PSG (PLAx), 2016 WL
22
10571773, at *3 (C.D. Cal. Oct. 25, 2016) (“[C]ourts have recognized that a defendant’s
23
state of mind in a securities case is the most difficult element of proof and one that is rarely
24
supported by direct evidence.”)).) Although Lead Counsel maintains that Plaintiff could
25
have confidently refuted Defendants’ scienter arguments at trial, Lead Counsel also
26
recognizes that a jury—with the power to make credibility determinations—could have
27
sided with Defendants. (Id. ¶ 83.) Lead Counsel further recognizes that Plaintiff faced
28
///
9
15-cv-00540-JLS-AGS
1
considerable challenges in proving loss causation and that Defendants’ allegedly
2
misleading statements inflated the price of Orexigen securities. (Id. ¶ 84.)
3
Additionally, were litigation to proceed, the parties may have engaged in another
4
round of dismissal arguments before beginning formal discovery, and given the complex
5
factual and legal issues in the case, Plaintiff opines that expert discovery would have been
6
extensive. (See Final App. Mot. at 20.) Had the parties not settled, they would have spent
7
considerable time and effort in discovery and litigating class certification and summary
8
judgment, adding “further expense to both sides as well as years of delay of any potential
9
recovery for the putative class.” (Id. at 20–21.)
10
The Final Approval Motion reassures the Court that Plaintiff—who spent “more than
11
six years [in] litigation, including undertaking a lengthy appellate process” before the Ninth
12
Circuit and Supreme Court—is fully aware of the strengths and weaknesses of this case.
13
(Id. at 21.) All in all, the outcome of this case was uncertain, and the Court agrees that
14
“[s]uch risks, when balanced against the immediate benefits of this Settlement, favor a
15
finding that the Settlement is reasonable.” (Abadou Decl. ¶ 83.) Accordingly, the Court
16
finds that these factors weigh in favor of approving the Settlement. See In re LinkedIn
17
User Priv. Litig, 309 F.R.D. 573, 587 (N.D. Cal. 2015) (“Generally, unless the settlement
18
is clearly inadequate, its acceptance and approval are preferable to a lengthy and expensive
19
litigation with uncertain results.”).
20
C.
21
Plaintiff’s risk of maintaining class action status throughout trial supports final
22
approval of the Settlement. In the Final Approval Motion, Plaintiff submits that the class
23
was not yet certified when the parties reached a settlement, and Defendants “undoubtedly
24
would have vigorously contested” certification of the putative class. (Final App. Mot. at
25
21.) Plaintiff also brings to light the additional complication of a potentially bifurcated
26
Class Period. (Id. at 22.) Indeed, in its Order granting in part Defendants’ Partial Motion
27
to Dismiss the CAC, the Court found that Plaintiff had not pled sufficient facts to support
28
a continuous class period and “effectively bifurcated the Class Period into two short
Risk of Maintaining Class Action Status Throughout Trial
10
15-cv-00540-JLS-AGS
1
windows”—March 3–5, 2015, and May 8–12, 2015—“substantially limit[ing] recoverable
2
damages.” (Id. at 20.) Further, because Plaintiff purchased common stock in March of
3
2015 only, Defendants would likely have challenged Plaintiff’s standing to bring claims
4
on behalf of those investors who purchased stock in May 2015, and, given that the events
5
complained of occurred in 2015, finding an individual willing to serve as a named plaintiff
6
would have been a “daunting exercise” for Lead Counsel. (Id. at 22.) The Settlement,
7
however, obviates the risk that potential unrepresented Class Members “might well have
8
lost their chance to recover.” Browne v. Am. Honda Motor Co., No. CV 09–06750 MMM
9
(DTBx), 2010 WL 9499072, at *11 (C.D. Cal. July 29, 2010). Accordingly, the Court
10
finds that this factor weighs in favor of approving the Settlement.
11
D.
12
The $4.8 million Settlement Amount supports final approval of the Settlement. As
13
provided in the Notice sent to potential Settlement Class Members, Plaintiff’s damages
14
expert estimates that, for the 25 million shares purchased during the Class Period, the
15
average recovery per share for Orexigen common stock will be approximately $0.19 per
16
share before deduction of attorneys’ fees, costs and expenses, and costs of providing notice
17
and administering the Settlement.
18
Claimant’s recovery will vary depending on, inter alia, when the Authorized Claimant
19
purchased or acquired Orexigen securities and when they were sold (Abadou Decl. ¶ 95),
20
the $4.8 million Settlement Amount represents approximately 25 percent of Plaintiff’s
21
expert’s estimated total potential damages (id. ¶ 77; Final App. Mot. at 8, 17). This
22
recovery is substantial considering that “the median settlement recovery for all securities
23
cases in 2020 represented just 1.7[ percent] of investor losses.” (Final App. Mot. at 17
24
(citing Janeen McIntosh & Svetlana Starykh, Recent Trends in Securities Class Action
25
Litigation: 2020 Full-Year Review, NERA Econ. Consulting (2021)). Moreover, the
26
Settlement yields immediate and certain recovery for the Class Members and is not
27
unreasonable in light of the risks, expenses, and likely duration of further litigation in a
28
///
Amount Offered in Settlement
(Rust Decl. at 17.)
Although each Authorized
11
15-cv-00540-JLS-AGS
1
case that has already been pending for more than six years. Accordingly, the Could finds
2
that the $4.8 million Settlement Amount weighs in favor of approving the Settlement.
3
E.
4
The stage of the proceedings in this case supports final approval of the Settlement.
5
As stated, the parties had been litigating this case for six years and had endured a lengthy
6
appellate process by the time the case settled. Lead Counsel, having extensively researched
7
and investigated the case and engaged in multiple rounds of dismissal proceedings,
8
“sufficiently knew and understood the merits of [Plaintiff’s] claims” before a settlement
9
was reached. (Final App. Mot. at 23–24.) Additionally, although the parties never began
10
formal discovery, they exchanged informal discovery, including documents in advance of
11
mediation, and Plaintiff engaged with experts to assess loss causation and damages. (Id.)
12
See also In re Mego Fin. Corp. Sec. Litig., 213 F.3d 454, 459 (9th Cir. 2000) (“[I]n the
13
context of class action settlements, formal discovery is not a necessary ticket to the
14
bargaining table where the parties have sufficient information to make an informed
15
decision about settlement.” (quoting Linney v. Cellular Alaska P’Ship, 151 F.3d 1234, 1239
16
(9th Cir. 1998))). The insight gained by Lead Counsel after six years of “extensive
17
investigation, substantial motion practice, hard-fought settlement negotiations[,] and
18
informal discovery” leaves little doubt that further discovery would aid in Lead Counsel’s
19
knowledge of the case and the strengths and weaknesses of Plaintiff’s claims. Accordingly,
20
the Court finds that this factor weighs in favor of approving the Settlement.
The Extent of Discovery Completed and Stage of the Proceedings
21
F.
22
Lead Counsel’s experience and belief that the Settlement is fair, reasonable, and in
23
the best interests of the Settlement Class supports final approval of the Settlement. Per the
24
firm resume attached to the Final Approval Motion, and as recognized by the Court in its
25
Preliminary Approval Order, Lead Counsel has extensive experience prosecuting complex
26
securities class actions. (See Prelim. App. Order at 147 at 9; ECF No. 149-4.) Given Lead
27
Counsel’s experience with the case and expertise with securities class actions, the Court
28
presumes reasonable Lead Counsel’s recommendation to approve the Settlement. See
Experience and Views of Counsel
12
15-cv-00540-JLS-AGS
1
Boyd v. Bechtel Corp., 485 F. Supp. 610, 622 (N.D. Cal. 1979) (“The recommendations of
2
plaintiffs’ counsel should be given a presumption of reasonableness. Attorneys, having an
3
intimate familiarity with a lawsuit after spending years in litigation, are in the best position
4
to evaluation the action . . . .”).
5
Additionally, although the Settlement was reached prior to class certification, no
6
circumstances of collusion appear here. The Settlement Class will receive an immediate
7
monetary benefit, the Stipulation of Settlement does not contain a “clear sailing” provision,
8
and any unclaimed fees will not revert back to Defendants but will be donated to an
9
appropriate and Court-approved 501(c)(3) non-profit organization. (See Final App. Mot.
10
at 25–26.) And, as addressed supra, the Settlement was negotiated and reached at arm’s
11
length with the assistance of an experienced, neutral mediator and both Lead Counsel and
12
defense counsel are capable and experienced. Accordingly, the Court finds that Lead
13
Counsel’s experience and opinion that the Settlement is fair, weighs in favor of approving
14
the Settlement.
15
G.
16
The reaction of the Class Members to the Settlement supports final approval of the
17
Settlement. As detailed above, the Claims Administrator, Rust, mailed 16,074 Notice
18
Packets to potential Settlement Class Members and nominees and had not received any
19
requests for exclusion from the Settlement Class as of October 19, 2021. (Supp. Rust Decl.
20
¶¶ 4–5.) Also as of October 21, 2021, Plaintiff had not received any objections to or
21
requests for exclusion from the Settlement, and the deadline to either object or to request
22
exclusion passed on October 7, 2021. (ECF No. 153-1 (“Supp. Abadou Decl.”) ¶ 7.) At
23
the Final Approval Hearing on October 28, 2021, Lead Counsel again confirmed that no
24
objections to or requests for exclusion from the Settlement had been received. Considering
25
the number of Notice Packets mailed to potential Class Members and the fact that zero
26
objections have been filed, the Court finds that the reaction of the Class Members to the
27
Settlement weighs in favor of approving the Settlement. See Nat’l Rural Telecomm. Coop.
28
v. DIRECTV, Inc., 221 F.R.D. 523, 529 (C.D. Cal. 2004) (“[T]he absence of a large number
Reaction of the Class Members to the Settlement
13
15-cv-00540-JLS-AGS
1
of objections to a proposed class action settlement raises a strong presumption that the
2
terms of a proposed class settlement action are favorable to the class members.”).
3
H.
4
Because all of the pertinent Harlon factors support final approval of the Settlement,
5
the Could finds that the Settlement is fair, reasonable, and adequate pursuant to Federal
6
Rule of Civil Procedure 23(e).
7
IV.
Conclusion
Plan of Allocation
8
In addition to the terms of the Settlement itself, the Court must determine whether
9
the Plan of Allocation (“Plan”) is fair, reasonable, and adequate. “Approval of a plan of
10
allocation of settlement proceeds in a class action under [Rule] 23 is governed by the same
11
standards of review applicable to approval of settlement as a whole: the plan must be fair,
12
reasonable and adequate.” In re Oracle Sec. Litig., No. C-90-0931-VRW, 1994 WL
13
502054, at *1 (N.D. Cal. June 16, 1994) (citing Class Plaintiffs v. City of Seattle, 955 F.2d
14
1268, 1284–85 (9th Cir. 1992)). “A plan of allocation that reimburses class members based
15
on the extent of their injuries is generally reasonable.” Id.
16
Here, Plaintiff prepared the Plan “after careful consideration and analysis” and with
17
the assistance of damages expert Dr. Zachary Nye. (Final Approval Mot. at 30.) The Plan
18
provides for a recognized loss formula to apportion the Net Settlement Fund to Authorized
19
Claimants based on when they acquired and/or sold Orexigen securities during the Class
20
Period and is designed to “equitably distribute the Net Settlement Fund among Authorized
21
Claimants based on their respective alleged economic losses as a result of [Defendants’]
22
alleged misstatements and omissions, as opposed to losses caused by the market- or
23
industry-wide factors, or company-specific factors unrelated to the alleged fraud.” (ECF
24
No. 149-7 at 24.) Further, the formula “ensures that Settlement Class Members’ recoveries
25
are based upon the relative losses they sustained” and that “[a]ll Settlement Class Members
26
will receive a pro rata distribution from the Net Settlement Fund calculated in the same
27
matter.” (Abadou Decl. ¶ 94.) The Plan “is not a formulized damage study but, rather, a
28
simplified methodology designed to compare one Settlement Class Member to another
14
15-cv-00540-JLS-AGS
1
through their respective Class Period transactions in Orexigen securities.” (Final App.
2
Mot. at 31.)
3
Having reviewed the Plan (ECF No. 149-7 ¶¶ 48–71), the Court finds that it is fair,
4
reasonable, and adequate, for it is based on a damages theory that Plaintiff developed in
5
consultation with a damages expert and aims to equitably distribute the Net Settlement
6
Funds based on each Authorized Claimant’s losses. See Schueneman v. Arena Pharms.,
7
Inc., Case No.: 3:10-CV-01959-CAB-(BLM), 2020 WL 3129566, at *7 (S.D. Cal. June 12,
8
2020) (finding a plan of allocation, which was recommended by lead counsel “after careful
9
consideration and analysis” and prepared “with the assistance of a damages expert,” fair
10
and adequate). Further lending support to this conclusion is the fact that zero Class
11
Members have requested exclusion from or filed objections to the Settlement.
12
V.
13
14
Conclusion
Because the Settlement and the Plan of Allocation are both fair, reasonable, and
adequate, the Court GRANTS the Final Approval Motion (ECF No. 149).
15
MOTION FOR ATTORNEYS’ FEES AND LITIGATION EXPENSES
16
Lead Plaintiff also moves for an order approving: (1) an award of $1,584,000 in
17
attorneys’ fees for Lead Counsel (33 percent of the $4.8 million Settlement Amount);
18
(2) an award of $100,529.65 in litigation expenses for Lead Counsel; and (3) a $9,230
19
incentive award to Lead Plaintiff. (Fees Mot. at 9.) Additionally, at the Final Approval
20
Hearing, Plaintiff orally requested that the Court approve reimbursement to Lead Counsel
21
of the reasonable costs and expenses incurred by Rust in connection with providing notice
22
and administrating the settlement in an amount not to exceed $250,000. The Court
23
addresses each request in turn.
24
I.
Attorneys’ Fees
25
A.
26
Federal Rule of Civil Procedure 23(h) permits a court to award reasonable attorneys’
27
fees “authorized by law or by the parties’ agreement.” In the Ninth Circuit, a district court
28
has discretion to apply either a lodestar method or a percentage-of-the-fund method in
Legal Standard
15
15-cv-00540-JLS-AGS
1
calculating a fee award in a common fund case. Fischel v. Equitable Life Assurance Soc’y
2
of U.S., 307 F.3d 997, 1006 (9th Cir. 2002). In this case, the Court finds that the
3
percentage-of-the-fund calculation is preferable to the lodestar approach. See Aichele v.
4
City of Los Angeles, Case No.: CV 12–10863–DMG (FFMx), 2015 WL 5286028, at *5
5
(C.D. Cal. Sept. 9, 2015) (“Many courts and commentators have recognized that the
6
percentage of the available fund analysis is the preferred approach in class action fee
7
requests because it more closely aligns the interests of the counsel and the class, i.e., class
8
counsel directly benefit from increasing the size of the class fund and working in the most
9
efficient manner.”); see also Vizcaino v. Microsoft Corp., 290 F.3d 1043, 1050 n.5 (9th
10
Cir. 2002) (“[I]t is widely recognized that the lodestar method creates incentives for
11
counsel to expend more hours than may be necessary on litigating a case so as to recover a
12
reasonable fee . . . .”).
13
When applying the percentage-of-the-fund approach, the Ninth Circuit has routinely
14
treated 25 percent as the “benchmark” a district court should award. In re Pac. Enters. Sec.
15
Litig., 47 F.3d 373, 379 (9th Cir. 1995) (citing Six (6) Mexican Workers v. Ariz. Citrus
16
Growers, 904 F.2d 1301, 1311 (9th Cir. 1990)); see also Fischel, 307 F.3d at 1006 (“We
17
have established a 25 percent ‘benchmark’ in percentage-of-the-fund cases . . . .”). The
18
district court, however, “may adjust the benchmark when special circumstances indicate a
19
higher or lower percentage would be appropriate.” In re Pac. Enters. Sec. Litig., 47 F.3d
20
at 379 (citing Six (6) Mexican Workers, 904 F.2d at 1311). “Selection of the benchmark
21
or any other rate,” whether higher or lower than 25 percent, “must be supported by findings
22
that take into account all of the circumstances of the case.” Vizcaino, 290 F.3d at 1048.
23
Relevant factors when determining the percentage ultimately awarded may include: (1) the
24
results achieved; (2) the risk of litigation; (3) the skill required and quality of work; (4) the
25
contingent nature of the fee and the financial burden carried by the plaintiffs; and (5)
26
awards made in similar cases. See id. at 1048–50. When using the percentage-of-the-fund
27
approach, district courts may also apply the lodestar method as a cross-check of the
28
reasonableness of the percentage award. See id. at 1050 (“[Although] the primary basis of
16
15-cv-00540-JLS-AGS
1
the fee award remains the percentage method, the lodestar may provide a useful perspective
2
on the reasonableness of a given percentage award.”); see also Aichele, 2015 WL 5286028,
3
at *2 (analyzing “comparison with counsel’s lodestar” as one of eight factors it considered
4
in determining the reasonableness of the requested percentage award).
5
B.
6
Considering the circumstances of this case, Lead Counsel’s departure from the 25
7
percent benchmark and request for 33 percent of the $4.8 million Settlement Amount in
8
attorneys’ fees, or $1,584,000, is reasonable. As highlighted by Lead Counsel in the Fees
9
Motion, several factors support Lead Counsel’s request for 33 percent of the Settlement
10
Amount. For one, Lead Counsel achieved significant results for the Settlement Class, as
11
the $4.8 million obtained represents approximately 25 percent of the estimated potential
12
damages in this action. (Fees Mot. at 13–14.) And having taken this case purely on a
13
contingency basis, Lead Counsel risked incurring significant costs and devoted a
14
substantial amount of time to this matter with no guarantee of compensation. (See id. at
15
14–15.) Counsel collectively “spent over four thousand hours researching, investigating,
16
and prosecuting this case on behalf of the putative class” and fronted “$100,529.65 in costs
17
and expenses,” again, with no guarantee of recovery. (Id. at 24.) Moreover, as discussed
18
supra, the risks of continuing this securities class action were not insignificant. (See id. at
19
14–17.)
Analysis
20
Departure from the 25 percent benchmark is further warranted when considering the
21
significant skill and extensive work demanded of Lead Counsel in this case. Lead Counsel,
22
among other things, expanded the originally alleged two-day Class Period after being
23
appointed Lead Counsel and thoroughly investigating the case (see id. at 17–19);
24
successfully appealed to the Ninth Circuit (see id. at 19–20); successfully challenged
25
Defendants’ request for en banc review (see id. at 20); successfully challenged Defendants’
26
petition for writ of certiorari to the Supreme Court (see id. at 20–21); retained bankruptcy
27
counsel to protect the interests in the putative class after Orexigen filed for bankruptcy (id.
28
at 22–23); and engaged in informal discovery in advance of mediation and prepared
17
15-cv-00540-JLS-AGS
1
“aggressive” mediation briefs (id. at 23–24). As detailed extensively in the Fees Motion
2
and described above, Lead Counsel overcame several hurdles before the parties settled the
3
case, and settlement may not have been reached without Lead Counsel’s skill and expertise.
4
Additionally, as several courts in the Ninth Circuit—including this Court—have
5
observed, attorneys’ fee awards from settlements involving a common fund, as this
6
Settlement involves, frequently exceed the 25 percent benchmark. Ford v. ECE Ent. Inc.,
7
Case No.: 14cv677 JLS (JLB), 2015 WL 11439033, at *5 (S.D. Cal. Dec. 14, 2015) (citing
8
In re Omnivision Techs., 559 F. Supp. 2d 1036, 1047 (N.D. Cal. 2008); Pokorny v. Quixtar,
9
Inc., CASE NO. C 07–0201 SC, 2013 WL 3790896, at *4 (N.D. Cal. July 18, 2013)); e.g.,
10
Jamil v. Workforce Res., Case No.: 18-CV-27 JLS (NLS), 2020 WL 6544660, at *4 (S.D.
11
Cal. Nov. 5, 2020) (approving an attorneys’ fees award of one-third of the common fund);
12
Howell v. Advantage RN, LLC, Case No.: 17-CV-883 JLS (BLM), 2020 WL 5847565, at
13
*5 (S.D. Cal. Oct. 1, 2020) (approving an attorneys’ fees award of one-third of the common
14
fund); Ruiz v. XPO Last Mile, Inc., Case No.: 5-CV-2125 JLS (KSC), 2017 WL 6513962,
15
at *8 (S.D. Cal. Dec. 20, 2017) (approving an attorneys’ fees award of 35 percent of the
16
common fund). Indeed, “[d]istrict courts in this circuit have routinely awarded fees of one-
17
third of the common fund or higher after considering the particular facts and circumstances
18
of each case,” and the Ninth Circuit has upheld such awards. See Beaver v. Tarsadia
19
Hotels, Case No. 11-cv-01842-GPC-KSC, 2017 WL 4310707, at *10 (S.D. Cal. Sept. 28,
20
2017) (collecting cases).
21
And again, no Class Member has objected to or requested exclusion from the
22
Settlement. As this Court has recognized in other cases, the reasonableness of Lead
23
Counsel’s fee request is bolstered by the reaction of the Settlement Class and the fact that
24
not a single Class Member has objected. See Nunez v. BAE Sys. San Diego Ship Repair
25
Inc., 292 F. Supp. 3d 1018, 1056 (S.D. Cal. 2017) (citing Singer v. Becton Dickinson &
26
Co., No. 08-CV-821-IEG (BLM), 2010 WL 2196104, at *9 (S.D. Cal. June 1, 2010) (noting
27
that the 33.33 percent fee request was “especially” warranted “in light of the fact that not
28
a single class member objected to” the request)).
18
15-cv-00540-JLS-AGS
1
Finally, the lodestar cross-check here yields a fractional multiplier, which further
2
supports Lead Counsel’s 33 percent fee request. See, e.g., In re Regulus Therapeutics Sec.
3
Litig., Case No.: 3:17-cv-182-BTM-RBB, Case No.: 3:17-cv-267-BTM-RBB, 2020 WL
4
6381898, at *8 (S.D. Cal. Oct. 30, 2020) (“[A] multiplier less than 1.0 is below the range
5
typically awarded by courts [in common fund cases] and is presumptively reasonable.”).
6
Collectively, Counsel expended 4,185.35 hours of work in this case, which amounts to
7
$2,995,448.75 in fees. (Abadou Decl. ¶¶ 118–30.) This lodestar amount compared against
8
the $1,584,000 requested in fees results in a fractional multiplier of 0.528. (Id. ¶ 119.) The
9
lodestar cross-check therefore provides a strong indication of the reasonableness of Lead
10
Counsel’s requested percentage award.
11
Having reviewed the Fees Motion and its supporting exhibits, Lead Counsel’s
12
arguments, and the applicable law, Lead Counsel’s request for 33 percent of the $4.8
13
million Settlement Amount is reasonable under the circumstances, particularly considering
14
the substantial results achieved, the risk to Lead Counsel in taking a complex securities
15
class action on contingency, the extensive amount of work demanded of Lead Counsel, and
16
the lodestar cross-check. Accordingly, the Court approves Lead Counsel’s request for 33
17
percent of the $4.8 million Settlement Amount, or $1,584,000, in attorneys’ fees.
18
II.
Litigation Expenses
19
Although the Settlement Agreement authorizes Lead Counsel to apply for
20
reimbursement of up to $185,000 in litigation expenses, Lead Counsel seeks
21
reimbursement of only $100,529.65 in expenses, plus interest at the same rate earned by
22
the Settlement Fund. (Fees Mot. at 28.) Lead Counsel’s expenses are documented in the
23
declarations attached to the Final Approval Motion (see Abadou Decl. ¶¶ 131–41; ECF
24
Nos. 149-8; 149-9), and the types of expenses that Lead Counsel seeks reimbursement for
25
include expert and consultant fees (Abadou Decl. ¶ 138); legal research costs (id. ¶ 139);
26
travel (id. ¶ 140); and miscellaneous costs related to printing and photocopying, postage,
27
transcript fees, mediation fees, court reporter fees, and court/filing fees (id. ¶ 141). As
28
these types of expenses are typically incurred by counsel in complex litigation and are
19
15-cv-00540-JLS-AGS
1
routinely charged to clients billed by the hour, they are recoverable. In re Omnivision
2
Techs., 559 F. Supp. 2d at 1049 (“Attorneys may recover their reasonable expenses that
3
would typically be billed to paying clients in non-contingency matters.”). Moreover, no
4
Class Member has objected to Lead Counsel’s request for reimbursement of expenses up
5
to $185,000.
6
Accordingly, because Lead Counsel’s expenses are typical and reasonable, the Court
7
approves Lead Counsel’s request for reimbursement of $100,529.65 in litigation expenses.
8
III.
Incentive Award
9
Plaintiff also seeks an incentive award of $9,230 “to compensate him for his service
10
to the Settlement Class . . . and to reimburse him for the reasonable costs incurred directly
11
from his work representing the Settlement Class.” (Abadou Decl. ¶ 146; see Fees Mot. at
12
29.) Although the PSLRA limits a class representative’s recovery to an amount “equal, on
13
a per share basis, to the portion of the final judgment or settlement awarded to all other
14
members of the class,” it does not preclude an “award of reasonable costs and expenses
15
(including lost wages) directly relating to the representation of the class to any
16
representative party serving on behalf of a class.” 15 U.S.C. § 78u-4(a)(4). Incentive
17
awards, like the one Plaintiff requests, are “fairly typical” and are “intended to compensate
18
class representatives for work done on behalf of the class, to make up for financial or
19
reputational risk undertaken in bringing the action, and, sometimes, to recognize their
20
willingness to act as a private attorney general.” Rodriguez v. W. Publ’g Corp., 563 F.3d
21
948, 958–59 (9th Cir. 2009).
22
To the Final Approval Motion, Plaintiff attached his own declaration detailing the
23
role he played in this case over the six years it has been pending. (ECF No. 149-10.)
24
Among other things, Plaintiff declares that he: (1) participated in meetings and
25
correspondence with Lead Counsel (id. ¶ 6); (2) reviewed correspondence, memoranda,
26
and court filings (id.); (3) reviewed draft pleadings and briefs, including those made in the
27
appellate and bankruptcy proceedings (id. ¶ 5); and (4) prepared for and participated in
28
settlement negotiations, mediation, and discussions concerning the terms of the Settlement
20
15-cv-00540-JLS-AGS
1
(id. ¶¶ 5, 7). Plaintiff further declares that he has devoted approximately 48 hours to this
2
case and calculates his average hourly rate, based on his own annual compensation, to be
3
$192.30. (Id. ¶ 9.)
4
Based on the representations made by Plaintiff in his declaration and the time he
5
spent assisting the case and fulfilling his obligations as a representative of the putative
6
class, the Court finds that Plaintiff’s requested incentive award is reasonable. Further,
7
Plaintiff’s requested award appears in line with others awarded in this District. See, e.g.,
8
In re Illumina, Inc. Sec. Litig., Case No.: 3:16-cv-3044-L-MSB, 2021 WL 1017295, at *8
9
(S.D. Cal. Mar. 17, 2021) (awarding class representative $25,000 for 70 hours of work, or
10
approximately $357 per hour); Mauss v. NuVasive, Inc., Case No.: 13cv2005 JM (JLB),
11
2018 WL 6421623, at *10 (S.D. Cal. Dec. 6, 2018) (awarding class representative $7,500
12
based on 38 hours of work in the case at an estimated rate of $200 per hour); see also In re
13
Regulus Therapeutics Inc. Sec. Litig., 2020 WL 6381898, at *8 (“Incentive awards
14
typically range from $2,000 to $10,000.” (quoting Bellinghausen v. Tractor Supply Co.,
15
306 F.R.D. 245, 267 (N.D. Cal. 2015))). Additionally, the Stipulation of Settlement
16
authorizes Plaintiff to receive reimbursement directly related to his representation of the
17
Settlement Class, and no Class Member has objected to this request. Accordingly, the
18
Court approves Plaintiff’s requested incentive award of $9,230.
19
IV.
Reimbursement of Claims Administration Costs
20
Lastly, Lead Counsel seeks approval of its request for reimbursement of the
21
reasonable costs and expenses incurred by Rust in connection with providing notice and
22
administering the Settlement. Lead Counsel did not specifically include this request in the
23
Fees Motion and instead made the request orally at the Final Approval Hearing. At the
24
Hearing, Lead Counsel represented that, because the claims administration is ongoing, it
25
did not yet have a final figure for the total claims administration costs.
26
As stated above, the Stipulation of Settlement authorizes a deduction of up to
27
$250,000 from the $4.8 million Settlement Amount for the reasonable costs and expenses
28
incurred by Rust in providing notice and administering the Settlement. Because the Court
21
15-cv-00540-JLS-AGS
1
approves the Settlement, and no Class Member has objected to the deduction of claims
2
administration costs from the Settlement Fund, the Court approves Lead Counsel’s request
3
for reimbursement of claims administration expenses up to $250,000, with any excess to
4
remain in the common fund.
5
V.
Conclusion
6
Because the requested attorneys’ fees, litigation expenses, and incentive award are
7
reasonable, the Court GRANTS the Fees Motion (ECF No. 150) and awards Lead Counsel
8
$1,584,000 in attorneys’ fees and $100,529.65 in litigation expenses and awards Lead
9
Plaintiff a $9,230 incentive award. Additionally, the Court GRANTS Lead Counsel’s oral
10
request for reimbursement of claims administration expenses up to $250,000.
11
CONCLUSION
For the foregoing reasons, the Court hereby GRANTS Lead Plaintiff’s Final
12
13
Approval Motion (ECF No. 149) and Fees Motion (ECF No. 150).
14
The Court CERTIFIES the Settlement Class for purposes of the Settlement and
15
APPROVES the Settlement and the Plan of Allocation as fair, reasonable, and adequate
16
pursuant to Federal Rule of Civil Procedure 23(e). The Court ORDERS the parties to
17
undertake the obligations set forth in the Stipulation of Settlement that arise out of this
18
Order.
19
The Court AWARDS attorneys’ fees to Lead Counsel in the amount of $1,584,000
20
and litigation expenses in the amount of $100,529.65. The Court also AUTHORIZES
21
Lead Counsel to deduct up to $250,000 from the Settlement Fund for reimbursement of
22
the claims administration expenses after the total claims administration expenses are
23
known.
24
The Court further AWARDS Plaintiff an incentive award in the amount of $9,230
25
for the work he performed as the class representative.
26
///
27
///
28
///
22
15-cv-00540-JLS-AGS
1
The Court DIRECTS the Clerk of Court to enter a separate judgment of dismissal
2
in accordance herewith and to close the case. Without affecting the finality of this Order,
3
the Court maintains jurisdiction with respect to the implementation and enforcement of the
4
terms of the Stipulation of Settlement.
5
6
IT IS SO ORDERED.
Dated: November 30, 2021
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
23
15-cv-00540-JLS-AGS
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
Why Is My Information Online?